ORGANOGENESIS HOLDINGS INC (ORGO) Fundamental Analysis & Valuation
NASDAQ:ORGO • US68621F1021
Current stock price
2.64 USD
-0.01 (-0.38%)
At close:
2.65 USD
+0.01 (+0.38%)
After Hours:
This ORGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ORGO Profitability Analysis
1.1 Basic Checks
- ORGO had positive earnings in the past year.
- In the past year ORGO has reported a negative cash flow from operations.
- ORGO had positive earnings in 4 of the past 5 years.
- Of the past 5 years ORGO 4 years had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of ORGO (2.65%) is better than 88.80% of its industry peers.
- ORGO has a Return On Equity of 3.65%. This is amongst the best in the industry. ORGO outperforms 89.96% of its industry peers.
- ORGO has a better Return On Invested Capital (8.83%) than 93.05% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 19.44%.
- The 3 year average ROIC (5.16%) for ORGO is below the current ROIC(8.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.65% | ||
| ROE | 3.65% | ||
| ROIC | 8.83% |
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
1.3 Margins
- Looking at the Profit Margin, with a value of 2.81%, ORGO belongs to the top of the industry, outperforming 88.61% of the companies in the same industry.
- In the last couple of years the Profit Margin of ORGO has declined.
- ORGO has a Operating Margin of 9.90%. This is amongst the best in the industry. ORGO outperforms 90.54% of its industry peers.
- ORGO's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 75.62%, ORGO belongs to the top of the industry, outperforming 83.20% of the companies in the same industry.
- In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | 2.81% | ||
| GM | 75.62% |
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
2. ORGO Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ORGO is creating some value.
- The number of shares outstanding for ORGO has been increased compared to 1 year ago.
- The number of shares outstanding for ORGO has been reduced compared to 5 years ago.
- Compared to 1 year ago, ORGO has a worse debt to assets ratio.
2.2 Solvency
- ORGO has an Altman-Z score of 3.00. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
- ORGO has a Altman-Z score of 3.00. This is in the better half of the industry: ORGO outperforms 67.18% of its industry peers.
- ORGO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.03, ORGO perfoms like the industry average, outperforming 43.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3 |
ROIC/WACC1.01
WACC8.75%
2.3 Liquidity
- A Current Ratio of 3.62 indicates that ORGO has no problem at all paying its short term obligations.
- The Current ratio of ORGO (3.62) is comparable to the rest of the industry.
- A Quick Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
- ORGO has a Quick ratio of 3.32. This is comparable to the rest of the industry: ORGO outperforms 41.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.32 |
3. ORGO Growth Analysis
3.1 Past
- ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.94%, which is quite impressive.
- ORGO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.72% yearly.
- The Revenue has grown by 17.04% in the past year. This is quite good.
- ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.77% yearly.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
3.2 Future
- ORGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
- The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. ORGO Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 10.15, the valuation of ORGO can be described as very reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 97.10% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 25.71. ORGO is valued rather cheaply when compared to this.
- ORGO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.15 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 99.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.6 |
4.3 Compensation for Growth
- The decent profitability rating of ORGO may justify a higher PE ratio.
- ORGO's earnings are expected to grow with 12.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.61
EPS Next 2Y12.92%
EPS Next 3YN/A
5. ORGO Dividend Analysis
5.1 Amount
- No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ORGO Fundamentals: All Metrics, Ratios and Statistics
2.64
-0.01 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)05-06 2026-05-06
Inst Owners54.15%
Inst Owner Change-0.51%
Ins Owners32.49%
Ins Owner Change1.24%
Market Cap339.61M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (228.41%)
Short Float %19.4%
Short Ratio15.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-244.44%
EPS NQ rev (3m)-244.44%
EPS NY rev (1m)-117.24%
EPS NY rev (3m)-117.24%
Revenue NQ rev (1m)-56.57%
Revenue NQ rev (3m)-56.57%
Revenue NY rev (1m)-13.79%
Revenue NY rev (3m)-13.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.15 | ||
| Fwd PE | N/A | ||
| P/S | 0.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.78 | ||
| P/tB | 0.86 | ||
| EV/EBITDA | 3.6 |
EPS(TTM)0.26
EY9.85%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.39
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)0.61
Graham Number4.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.65% | ||
| ROE | 3.65% | ||
| ROCE | 11.21% | ||
| ROIC | 8.83% | ||
| ROICexc | 10.88% | ||
| ROICexgc | 12% | ||
| OM | 9.9% | ||
| PM (TTM) | 2.81% | ||
| GM | 75.62% | ||
| FCFM | N/A |
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 76.1% | ||
| Cap/Sales | 2.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.32 | ||
| Altman-Z | 3 |
F-Score2
WACC8.75%
ROIC/WACC1.01
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year-3.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
What is the profitability of ORGO stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.
What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?
The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.